Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of Soleno Therapeutics Inc (NASDAQ: SLNO) was $56.58 for the day, up 3.36% from the previous closing price of $54.74. In other words, the price has increased by $3.36 from its previous closing price. On the day, 1.96 million shares were traded. SLNO stock price reached its highest trading level at $58.25 during the session, while it also had its lowest trading level at $53.88.
Ratios:
Our analysis of SLNO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 15.01 and its Current Ratio is at 15.13. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.22.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, Wells Fargo on August 20, 2025, initiated with a Overweight rating and assigned the stock a target price of $123.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 11 ’25 when Abingworth Bioventures VII LP bought 1,347,522 shares for $82.15 per share.
Hirano Patricia C sold 3,830 shares of SLNO for $316,971 on Jul 01 ’25. The insider now owns 13,206 shares after completing the transaction at $82.76 per share. On Jul 01 ’25, another insider, PATRICIA HIRANO, who serves as the Officer of the company, bought 3,830 shares for $82.76 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SLNO now has a Market Capitalization of 3006944768 and an Enterprise Value of 2772872704. For the stock, the TTM Price-to-Sale (P/S) ratio is 92.07 while its Price-to-Book (P/B) ratio in mrq is 11.88. Its current Enterprise Value per Revenue stands at 84.909 whereas that against EBITDA is -15.044.
Stock Price History:
The Beta on a monthly basis for SLNO is -2.78, which has changed by 0.2069112 over the last 52 weeks, in comparison to a change of 0.1675967 over the same period for the S&P500. Over the past 52 weeks, SLNO has reached a high of $90.32, while it has fallen to a 52-week low of $41.50. The 50-Day Moving Average of the stock is -23.20%, while the 200-Day Moving Average is calculated to be -12.02%.
Shares Statistics:
SLNO traded an average of 1.76M shares per day over the past three months and 3327640 shares per day over the past ten days. A total of 50.44M shares are outstanding, with a floating share count of 46.02M. Insiders hold about 13.40% of the company’s shares, while institutions hold 96.49% stake in the company. Shares short for SLNO as of 1756425600 were 7582159 with a Short Ratio of 4.31, compared to 1753920000 on 6040860. Therefore, it implies a Short% of Shares Outstanding of 7582159 and a Short% of Float of 16.290002.
Earnings Estimates
The dynamic stock of Soleno Therapeutics Inc (SLNO) is currently attracting attention from 11.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $0.2, with high estimates of $0.62 and low estimates of -$0.41.
Analysts are recommending an EPS of between $0.24 and -$1.69 for the fiscal current year, implying an average EPS of -$0.7. EPS for the following year is $3.0, with 11.0 analysts recommending between $5.56 and $1.01.
Revenue Estimates
For the next quarter, 10 analysts are estimating revenue of $61.6M. There is a high estimate of $83M for the next quarter, whereas the lowest estimate is $40.2M.
Based on 10 analysts’ estimates, the company’s revenue will be $397.47M in the next fiscal year. The high estimate is $551.75M and the low estimate is $252.18M.
